Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 51 entries
Sorted by: Best Match Show Resources per page
Reconsideration ICF scheme.

Disability and rehabilitation

Heerkens YF, de Weerd M, Huber M, de Brouwer CPM, van der Veen S, Perenboom RJM, van Gool CH, Ten Napel H, van Bon-Martens M, Stallinga HA, van Meeteren NLU.
PMID: 28903603
Disabil Rehabil. 2018 Jan;40(1):121-122. doi: 10.1080/09638288.2017.1378390. Epub 2017 Sep 13.

No abstract available.

Cite
Heerkens YF, de Weerd M, Huber M, et al. Reconsideration ICF scheme. Disabil Rehabil. 2017;40(1):121-122doi: 10.1080/09638288.2017.1378390.
Heerkens, Y. F., de Weerd, M., Huber, M., de Brouwer, C. P. M., van der Veen, S., Perenboom, R. J. M., van Gool, C. H., Ten Napel, H., van Bon-Martens, M., Stallinga, H. A., & van Meeteren, N. L. U. (2018). Reconsideration ICF scheme. Disability and rehabilitation, 40(1), 121-122. https://doi.org/10.1080/09638288.2017.1378390
Heerkens, Yvonne F, et al. "Reconsideration ICF scheme." Disability and rehabilitation vol. 40,1 (2018): 121-122. doi: https://doi.org/10.1080/09638288.2017.1378390
Heerkens YF, de Weerd M, Huber M, de Brouwer CPM, van der Veen S, Perenboom RJM, van Gool CH, Ten Napel H, van Bon-Martens M, Stallinga HA, van Meeteren NLU. Reconsideration ICF scheme. Disabil Rehabil. 2018 Jan;40(1):121-122. doi: 10.1080/09638288.2017.1378390. Epub 2017 Sep 13. PMID: 28903603.
Copy Download .nbib Format: NLM
Transformation of Brassica napus and Brassica oleracea Using Agrobacterium tumefaciens and the Expression of the bar and neo Genes in the Transgenic Plants.

Plant physiology

De Block M, De Brouwer D, Tenning P.
PMID: 16667089
Plant Physiol. 1989 Oct;91(2):694-701. doi: 10.1104/pp.91.2.694.

An efficient and largely genotype-independent transformation method for Brassica napus and Brassica oleracea was established based on neo or bar as selectable marker genes. Hypocotyl explants of Brassica napus and Brassica oleracea cultivars were infected with Agrobacterium strains containing...

Cite
De Block M, De Brouwer D, Tenning P. Transformation of Brassica napus and Brassica oleracea Using Agrobacterium tumefaciens and the Expression of the bar and neo Genes in the Transgenic Plants. Plant Physiol. 1989;91(2):694-701doi: 10.1104/pp.91.2.694.
De Block, M., De Brouwer, D., & Tenning, P. (1989). Transformation of Brassica napus and Brassica oleracea Using Agrobacterium tumefaciens and the Expression of the bar and neo Genes in the Transgenic Plants. Plant physiology, 91(2), 694-701. https://doi.org/10.1104/pp.91.2.694
De Block, M, et al. "Transformation of Brassica napus and Brassica oleracea Using Agrobacterium tumefaciens and the Expression of the bar and neo Genes in the Transgenic Plants." Plant physiology vol. 91,2 (1989): 694-701. doi: https://doi.org/10.1104/pp.91.2.694
De Block M, De Brouwer D, Tenning P. Transformation of Brassica napus and Brassica oleracea Using Agrobacterium tumefaciens and the Expression of the bar and neo Genes in the Transgenic Plants. Plant Physiol. 1989 Oct;91(2):694-701. doi: 10.1104/pp.91.2.694. PMID: 16667089; PMCID: PMC1062058.
Copy Download .nbib Format: NLM
Periventricular heterotopia in common microdeletion syndromes.

Molecular syndromology

van Kogelenberg M, Ghedia S, McGillivray G, Bruno D, Leventer R, Macdermot K, Nelson J, Nagarajan L, Veltman JA, de Brouwer AP, McKinlay Gardner RJ, van Bokhoven H, Kirk EP, Robertson SP.
PMID: 20648244
Mol Syndromol. 2010 Feb;1(1):35-41. doi: 10.1159/000274491. Epub 2010 Jan 08.

Periventricular heterotopia (PH) is a brain malformation characterised by heterotopic nodules of neurons lining the walls of the cerebral ventricles. Mutations in FLNA account for 20-24% of instances but a majority have no identifiable genetic aetiology. Often the co-occurrence...

Cite
van Kogelenberg M, Ghedia S, McGillivray G, et al. Periventricular heterotopia in common microdeletion syndromes. Mol Syndromol. 2010;1(1):35-41doi: 10.1159/000274491.
van Kogelenberg, M., Ghedia, S., McGillivray, G., Bruno, D., Leventer, R., Macdermot, K., Nelson, J., Nagarajan, L., Veltman, J. A., de Brouwer, A. P., McKinlay Gardner, R. J., van Bokhoven, H., Kirk, E. P., & Robertson, S. P. (2010). Periventricular heterotopia in common microdeletion syndromes. Molecular syndromology, 1(1), 35-41. https://doi.org/10.1159/000274491
van Kogelenberg, M, et al. "Periventricular heterotopia in common microdeletion syndromes." Molecular syndromology vol. 1,1 (2010): 35-41. doi: https://doi.org/10.1159/000274491
van Kogelenberg M, Ghedia S, McGillivray G, Bruno D, Leventer R, Macdermot K, Nelson J, Nagarajan L, Veltman JA, de Brouwer AP, McKinlay Gardner RJ, van Bokhoven H, Kirk EP, Robertson SP. Periventricular heterotopia in common microdeletion syndromes. Mol Syndromol. 2010 Feb;1(1):35-41. doi: 10.1159/000274491. Epub 2010 Jan 08. PMID: 20648244; PMCID: PMC2883850.
Copy Download .nbib Format: NLM
The EMPCAN study: protocol of a population-based cohort study on the evolution of the socio-economic position of workers with cancer.

Archives of public health = Archives belges de sante publique

Kiasuwa-Mbengi RL, Nyaga V, Otter R, de Brouwer C, Bouland C.
PMID: 30937166
Arch Public Health. 2019 Mar 20;77:15. doi: 10.1186/s13690-019-0337-1. eCollection 2019.

BACKGROUND: The improvements in cancer control led to an increase in the number of cancer survivors, notably, in the working age population (16-64 years). There is a strong need to assess and understand their reintegration on the labour market,...

Cite
Kiasuwa-Mbengi RL, Nyaga V, Otter R, et al. The EMPCAN study: protocol of a population-based cohort study on the evolution of the socio-economic position of workers with cancer. Arch Public Health. 2019;77:15doi: 10.1186/s13690-019-0337-1.
Kiasuwa-Mbengi, R. L., Nyaga, V., Otter, R., de Brouwer, C., & Bouland, C. (2019). The EMPCAN study: protocol of a population-based cohort study on the evolution of the socio-economic position of workers with cancer. Archives of public health = Archives belges de sante publique, 7715. https://doi.org/10.1186/s13690-019-0337-1
Kiasuwa-Mbengi, Régine L, et al. "The EMPCAN study: protocol of a population-based cohort study on the evolution of the socio-economic position of workers with cancer." Archives of public health = Archives belges de sante publique vol. 77 (2019): 15. doi: https://doi.org/10.1186/s13690-019-0337-1
Kiasuwa-Mbengi RL, Nyaga V, Otter R, de Brouwer C, Bouland C. The EMPCAN study: protocol of a population-based cohort study on the evolution of the socio-economic position of workers with cancer. Arch Public Health. 2019 Mar 20;77:15. doi: 10.1186/s13690-019-0337-1. eCollection 2019. PMID: 30937166; PMCID: PMC6427850.
Copy Download .nbib Format: NLM
Confirming TDP2 mutation in spinocerebellar ataxia autosomal recessive 23 (SCAR23).

Neurology. Genetics

Zagnoli-Vieira G, Bruni F, Thompson K, He L, Walker S, de Brouwer APM, Taylor RW, Niyazov D, Caldecott KW.
PMID: 30109272
Neurol Genet. 2018 Aug 01;4(4):e262. doi: 10.1212/NXG.0000000000000262. eCollection 2018 Aug.

OBJECTIVE: To address the relationship between mutations in the DNA strand break repair protein tyrosyl DNA phosphodiesterase 2 (TDP2) and spinocerebellar ataxia autosomal recessive 23 (SCAR23) and to characterize the cellular phenotype of primary fibroblasts from this disease.METHODS: We...

Cite
Zagnoli-Vieira G, Bruni F, Thompson K, et al. Confirming TDP2 mutation in spinocerebellar ataxia autosomal recessive 23 (SCAR23). Neurol Genet. 2018;4(4):e262doi: 10.1212/NXG.0000000000000262.
Zagnoli-Vieira, G., Bruni, F., Thompson, K., He, L., Walker, S., de Brouwer, A. P. M., Taylor, R. W., Niyazov, D., & Caldecott, K. W. (2018). Confirming TDP2 mutation in spinocerebellar ataxia autosomal recessive 23 (SCAR23). Neurology. Genetics, 4(4), e262. https://doi.org/10.1212/NXG.0000000000000262
Zagnoli-Vieira, Guido, et al. "Confirming TDP2 mutation in spinocerebellar ataxia autosomal recessive 23 (SCAR23)." Neurology. Genetics vol. 4,4 (2018): e262. doi: https://doi.org/10.1212/NXG.0000000000000262
Zagnoli-Vieira G, Bruni F, Thompson K, He L, Walker S, de Brouwer APM, Taylor RW, Niyazov D, Caldecott KW. Confirming TDP2 mutation in spinocerebellar ataxia autosomal recessive 23 (SCAR23). Neurol Genet. 2018 Aug 01;4(4):e262. doi: 10.1212/NXG.0000000000000262. eCollection 2018 Aug. PMID: 30109272; PMCID: PMC6089694.
Copy Download .nbib Format: NLM
Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial.

JACC. Basic to translational science

Leucker TM, Osburn WO, Reventun P, Smith K, Claggett B, Kirwan BA, de Brouwer S, Williams MS, Gerstenblith G, Hager DN, Streiff MB, Solomon SD, Lowenstein CJ.
PMID: 34904132
JACC Basic Transl Sci. 2021 Dec 08; doi: 10.1016/j.jacbts.2021.09.013. Epub 2021 Dec 08.

COVID-19 is characterized by vascular inflammation and thrombosis, including elevations in P-selectin, a mediator of inflammation released by endothelial cells. We tested the effect of P-selectin inhibition on biomarkers of thrombosis and inflammation in patients with COVID-19. Hospitalized patients...

Cite
Leucker TM, Osburn WO, Reventun P, et al. Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial. JACC Basic Transl Sci. 2021;doi: 10.1016/j.jacbts.2021.09.013.
Leucker, T. M., Osburn, W. O., Reventun, P., Smith, K., Claggett, B., Kirwan, B. A., de Brouwer, S., Williams, M. S., Gerstenblith, G., Hager, D. N., Streiff, M. B., Solomon, S. D., & Lowenstein, C. J. (2021). Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial. JACC. Basic to translational science, . https://doi.org/10.1016/j.jacbts.2021.09.013
Leucker, Thorsten M, et al. "Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial." JACC. Basic to translational science vol. (2021). doi: https://doi.org/10.1016/j.jacbts.2021.09.013
Leucker TM, Osburn WO, Reventun P, Smith K, Claggett B, Kirwan BA, de Brouwer S, Williams MS, Gerstenblith G, Hager DN, Streiff MB, Solomon SD, Lowenstein CJ. Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial. JACC Basic Transl Sci. 2021 Dec 08; doi: 10.1016/j.jacbts.2021.09.013. Epub 2021 Dec 08. PMID: 34904132; PMCID: PMC8653991.
Copy Download .nbib Format: NLM
Escitalopram and lorazepam differentially affect nesting and open field behaviour in deer mice exposed to an anxiogenic environment.

Neuroscience research

Wolmarans W, Prinsloo M, Seedat S, Stein DJ, Harvey BH, de Brouwer G.
PMID: 34736961
Neurosci Res. 2021 Nov 01; doi: 10.1016/j.neures.2021.10.011. Epub 2021 Nov 01.

Large nest building behaviour (LNB), as expressed by a subpopulation of laboratory housed deer mice (Peromyscus maniculatus bairdii), is persistent and repetitive. However, the response of LNB to an anxiogenic environment has not yet been investigated. Here, we employed...

Cite
Wolmarans W, Prinsloo M, Seedat S, et al. Escitalopram and lorazepam differentially affect nesting and open field behaviour in deer mice exposed to an anxiogenic environment. Neurosci Res. 2021;doi: 10.1016/j.neures.2021.10.011.
Wolmarans, W., Prinsloo, M., Seedat, S., Stein, D. J., Harvey, B. H., & de Brouwer, G. (2021). Escitalopram and lorazepam differentially affect nesting and open field behaviour in deer mice exposed to an anxiogenic environment. Neuroscience research, . https://doi.org/10.1016/j.neures.2021.10.011
Wolmarans, De Wet, et al. "Escitalopram and lorazepam differentially affect nesting and open field behaviour in deer mice exposed to an anxiogenic environment." Neuroscience research vol. (2021). doi: https://doi.org/10.1016/j.neures.2021.10.011
Wolmarans W, Prinsloo M, Seedat S, Stein DJ, Harvey BH, de Brouwer G. Escitalopram and lorazepam differentially affect nesting and open field behaviour in deer mice exposed to an anxiogenic environment. Neurosci Res. 2021 Nov 01; doi: 10.1016/j.neures.2021.10.011. Epub 2021 Nov 01. PMID: 34736961.
Copy Download .nbib Format: NLM
Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial.

JACC. Basic to translational science

Leucker TM, Osburn WO, Reventun P, Smith K, Claggett B, Kirwan BA, de Brouwer S, Williams MS, Gerstenblith G, Hager DN, Streiff MB, Solomon SD, Lowenstein CJ.
PMID: 34904132
JACC Basic Transl Sci. 2021 Dec;6(12):935-945. doi: 10.1016/j.jacbts.2021.09.013. Epub 2021 Dec 08.

COVID-19 is characterized by vascular inflammation and thrombosis, including elevations in P-selectin, a mediator of inflammation released by endothelial cells. We tested the effect of P-selectin inhibition on biomarkers of thrombosis and inflammation in patients with COVID-19. Hospitalized patients...

Cite
Leucker TM, Osburn WO, Reventun P, et al. Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial. JACC Basic Transl Sci. 2021;6(12):935-945doi: 10.1016/j.jacbts.2021.09.013.
Leucker, T. M., Osburn, W. O., Reventun, P., Smith, K., Claggett, B., Kirwan, B. A., de Brouwer, S., Williams, M. S., Gerstenblith, G., Hager, D. N., Streiff, M. B., Solomon, S. D., & Lowenstein, C. J. (2021). Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial. JACC. Basic to translational science, 6(12), 935-945. https://doi.org/10.1016/j.jacbts.2021.09.013
Leucker, Thorsten M, et al. "Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial." JACC. Basic to translational science vol. 6,12 (2021): 935-945. doi: https://doi.org/10.1016/j.jacbts.2021.09.013
Leucker TM, Osburn WO, Reventun P, Smith K, Claggett B, Kirwan BA, de Brouwer S, Williams MS, Gerstenblith G, Hager DN, Streiff MB, Solomon SD, Lowenstein CJ. Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial. JACC Basic Transl Sci. 2021 Dec;6(12):935-945. doi: 10.1016/j.jacbts.2021.09.013. Epub 2021 Dec 08. PMID: 34904132; PMCID: PMC8653991.
Copy Download .nbib Format: NLM
[No title available]

Tijdschrift voor bedrijfs- en verzekeringsgeneeskunde

de Brouwer H.
PMID: 33144754
Tijdschr Bedr Verzekeringsgeneeskd. 2020;28(10):57. doi: 10.1007/s12498-020-1301-2. Epub 2020 Nov 06.

No abstract available.

Cite
de Brouwer H. NVVG. . Tijdschr Bedr Verzekeringsgeneeskd. 2020;28(10):57doi: 10.1007/s12498-020-1301-2.
de Brouwer, H. (2020). NVVG. . Tijdschrift voor bedrijfs- en verzekeringsgeneeskunde, 28(10), 57. https://doi.org/10.1007/s12498-020-1301-2
de Brouwer, Hans. "NVVG." . Tijdschrift voor bedrijfs- en verzekeringsgeneeskunde vol. 28,10 (2020): 57. doi: https://doi.org/10.1007/s12498-020-1301-2
de Brouwer H. NVVG. . Tijdschr Bedr Verzekeringsgeneeskd. 2020;28(10):57. doi: 10.1007/s12498-020-1301-2. Epub 2020 Nov 06. Dutch. PMID: 33144754; PMCID: PMC7594992.
Copy Download .nbib Format: NLM
Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST).

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation

Te Rijdt WP, Hoorntje ET, de Brouwer R, Oomen A, Amin A, van der Heijden JF, Karper JC, Westenbrink BD, Silljé HHW, Te Riele ASJM, Wiesfeld ACP, van Gelder IC, Willems TP, van der Zwaag PA, van Tintelen JP, Hillege JH, Tan HL, van Veldhuisen DJ, Asselbergs FW, de Boer RA, Wilde AAM, van den Berg MP.
PMID: 34143416
Neth Heart J. 2021 Jun 18; doi: 10.1007/s12471-021-01584-5. Epub 2021 Jun 18.

BACKGROUND: The p.Arg14del (c.40_42delAGA) phospholamban (PLN) pathogenic variant is a founder mutation that causes dilated cardiomyopathy (DCM) and arrhythmogenic cardiomyopathy (ACM). Carriers are at increased risk of malignant ventricular arrhythmias and heart failure, which has been ascribed to cardiac...

Cite
Te Rijdt WP, Hoorntje ET, de Brouwer R, et al. Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST). Neth Heart J. 2021;doi: 10.1007/s12471-021-01584-5.
Te Rijdt, W. P., Hoorntje, E. T., de Brouwer, R., Oomen, A., Amin, A., van der Heijden, J. F., Karper, J. C., Westenbrink, B. D., Silljé, H. H. W., Te Riele, A. S. J. M., Wiesfeld, A. C. P., van Gelder, I. C., Willems, T. P., van der Zwaag, P. A., van Tintelen, J. P., Hillege, J. H., Tan, H. L., van Veldhuisen, D. J., Asselbergs, F. W., de Boer, R. A., Wilde, A. A. M., & van den Berg, M. P. (2021). Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST). Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, . https://doi.org/10.1007/s12471-021-01584-5
Te Rijdt, W P, et al. "Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST)." Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation vol. (2021). doi: https://doi.org/10.1007/s12471-021-01584-5
Te Rijdt WP, Hoorntje ET, de Brouwer R, Oomen A, Amin A, van der Heijden JF, Karper JC, Westenbrink BD, Silljé HHW, Te Riele ASJM, Wiesfeld ACP, van Gelder IC, Willems TP, van der Zwaag PA, van Tintelen JP, Hillege JH, Tan HL, van Veldhuisen DJ, Asselbergs FW, de Boer RA, Wilde AAM, van den Berg MP. Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST). Neth Heart J. 2021 Jun 18; doi: 10.1007/s12471-021-01584-5. Epub 2021 Jun 18. PMID: 34143416.
Copy Download .nbib Format: NLM
Cost-effectiveness of sensor-augmented insulin pump therapy vs continuous subcutaneous insulin infusion in patients with type 1 diabetes in the Netherlands.

ClinicoEconomics and outcomes research : CEOR

Roze S, Smith-Palmer J, de Portu S, Delbaere A, de Brouwer B, de Valk HW.
PMID: 30679914
Clinicoecon Outcomes Res. 2019 Jan 14;11:73-82. doi: 10.2147/CEOR.S186298. eCollection 2019.

AIM: The aim of this study was to perform a cost-effectiveness analysis to establish the cost-effectiveness of sensor-augmented pump therapy (SAP) with automated insulin suspension vs continuous subcutaneous insulin infusion (CSII) alone in patients with type 1 diabetes in...

Cite
Roze S, Smith-Palmer J, de Portu S, et al. Cost-effectiveness of sensor-augmented insulin pump therapy vs continuous subcutaneous insulin infusion in patients with type 1 diabetes in the Netherlands. Clinicoecon Outcomes Res. 2019;11:73-82doi: 10.2147/CEOR.S186298.
Roze, S., Smith-Palmer, J., de Portu, S., Delbaere, A., de Brouwer, B., & de Valk, H. W. (2019). Cost-effectiveness of sensor-augmented insulin pump therapy vs continuous subcutaneous insulin infusion in patients with type 1 diabetes in the Netherlands. ClinicoEconomics and outcomes research : CEOR, 1173-82. https://doi.org/10.2147/CEOR.S186298
Roze, Stephané, et al. "Cost-effectiveness of sensor-augmented insulin pump therapy vs continuous subcutaneous insulin infusion in patients with type 1 diabetes in the Netherlands." ClinicoEconomics and outcomes research : CEOR vol. 11 (2019): 73-82. doi: https://doi.org/10.2147/CEOR.S186298
Roze S, Smith-Palmer J, de Portu S, Delbaere A, de Brouwer B, de Valk HW. Cost-effectiveness of sensor-augmented insulin pump therapy vs continuous subcutaneous insulin infusion in patients with type 1 diabetes in the Netherlands. Clinicoecon Outcomes Res. 2019 Jan 14;11:73-82. doi: 10.2147/CEOR.S186298. eCollection 2019. PMID: 30679914; PMCID: PMC6336135.
Copy Download .nbib Format: NLM
Reconsideration of the scheme of the international classification of functioning, disability and health: incentives from the Netherlands for a global debate.

Disability and rehabilitation

Heerkens YF, de Weerd M, Huber M, de Brouwer CPM, van der Veen S, Perenboom RJM, van Gool CH, Ten Napel H, van Bon-Martens M, Stallinga HA, van Meeteren NLU.
PMID: 28129712
Disabil Rehabil. 2018 Mar;40(5):603-611. doi: 10.1080/09638288.2016.1277404. Epub 2017 Jan 27.

PURPOSE: The ICF (International Classification of Functioning, Disability and Health) framework (used worldwide to describe 'functioning' and 'disability'), including the ICF scheme (visualization of functioning as result of interaction with health condition and contextual factors), needs reconsideration. The purpose...

Cite
Heerkens YF, de Weerd M, Huber M, et al. Reconsideration of the scheme of the international classification of functioning, disability and health: incentives from the Netherlands for a global debate. Disabil Rehabil. 2017;40(5):603-611doi: 10.1080/09638288.2016.1277404.
Heerkens, Y. F., de Weerd, M., Huber, M., de Brouwer, C. P. M., van der Veen, S., Perenboom, R. J. M., van Gool, C. H., Ten Napel, H., van Bon-Martens, M., Stallinga, H. A., & van Meeteren, N. L. U. (2018). Reconsideration of the scheme of the international classification of functioning, disability and health: incentives from the Netherlands for a global debate. Disability and rehabilitation, 40(5), 603-611. https://doi.org/10.1080/09638288.2016.1277404
Heerkens, Yvonne F, et al. "Reconsideration of the scheme of the international classification of functioning, disability and health: incentives from the Netherlands for a global debate." Disability and rehabilitation vol. 40,5 (2018): 603-611. doi: https://doi.org/10.1080/09638288.2016.1277404
Heerkens YF, de Weerd M, Huber M, de Brouwer CPM, van der Veen S, Perenboom RJM, van Gool CH, Ten Napel H, van Bon-Martens M, Stallinga HA, van Meeteren NLU. Reconsideration of the scheme of the international classification of functioning, disability and health: incentives from the Netherlands for a global debate. Disabil Rehabil. 2018 Mar;40(5):603-611. doi: 10.1080/09638288.2016.1277404. Epub 2017 Jan 27. PMID: 28129712.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 51 entries